A prognostic immune risk score for diffuse large B‐cell lymphoma.

Summary: We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371n = 206 and GSE117556n = 445 combined) cohorts. Proportions of non‐lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non‐lymphoma immune cells calculated using the CIBERSORT algorithm. Five‐year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P < 0·001). HR in the validation cohort was HR = 2·17 (1·47, 3·21; P < 0·001). Enrichment analyses indicated correlations with genes controlling immune‐related biological processes and pathways. A nomogram comprised of the immune risk score and most covariates including age, lactate dehydrogenase concentration (LDH), lymphoma‐type (germinal centre B cell [GCB] versus non‐GCB), Eastern Cooperative Oncology Group performance status (ECOG‐PS) and rituximab therapy had a C‐statistic of 0·76 compared with C‐statistics of 0·69 and 0·69 for the International Prognostic Index (IPI) and Revised International Prognostic Index (R‐IPI). These data indicate the immune risk score is an accurate, independent survival predictor in persons with DLBCL. [ABSTRACT FROM AUTHOR]